https://orcid.org/0000-0002-4739-265X
References
- Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019;18(2):139–158.
- Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14:263–292.
- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):10810.
- Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374.
- DeBaun MR, Ghafuri DL, Rodeghier M, et al. Decreased medial survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood. 2019;133(6):615–617.
- Lee S, Vania DK, Bhor M, et al. Patient-reported outcomes and economic burden of adults with sickle cell disease in the United States: a systematic review. Int J Gen Med. 2020;13:361–377.
- Campbell A, Cong Z, Agodoa I, et al. The economic burden of end-organ damage among medicaid patients with sickle cell disease in the United States: a population based longitudinal claims study. J Manag Care Spec Pharm. 2020;26(9):1121–1129.
- Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323–327.
- Shah N, Bhor M, Xie L, et al. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. Health Qual Life Outcomes. 2019;17(1):155.
- Shah NR, Bhor M, Latremouille-Viau D, et al. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, medicaid, and medicare insurance – the perspective of private and public payers. J Med Econ. 2020;23(11):1345–1355.
- Holdford D, Vendetti N, Sop DM, et al. Indirect economic burden of sickle cell disease. Value Health. 2021;24(8):1095–1101.
- Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol. 2009;84(6):320–322.
- Carroll CP, Haywood C, Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large urban medicaid managed care organization. Am J Hematol. 2009;84(10):666–670.
- Johnson KM, Jiao B, Ramsey SD, et al. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2022. DOI:10.1182/bloodadvances.2021006281
- Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005;105(2):545–547.
- Hankins J, Jeng M, Harris S, et al. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol. 2005;27(3):158–161.
- Badawy SM, Beg U, Liem RI, et al. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv. 2021;5(2):570–583.
- Inusa BPD, Stewart CE, Mathurin-Charles S, et al. Paediatric to adult transition care for patients with sickle cell disease: a global perspective. Lancet Haematol. 2020;7(4):e329–e341.
- Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447–3452.
- Colombatti R, Sainati L, Trevisanuto D. Anemia and transfusion in the neonate. Semin Fetal Neonatal Med. 2016;21(1):2–9.
- Lanzkron S, Sawicki GS, Hassell KL, et al. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: current practices and research priorties. J Clin Transl Sci. 2018;2(5):334–342.
- Buchanan G, Vichinsky E, Krishnamurti L, et al. Severe sickle cell disease – pathophysiology and therapy. Biol Blood Marrow Transplant. 2010;16(1):S64–S67.
- Blinder MA, Vekeman F, Sasane M, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer. 2013;60(5):828–835.
- van Beers EJ, van Tuijn CFJ, Mac Gillavry MR, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. Haematologica. 2008;93(5):757–760.
- Vekeman F, Sasane M, Cheng WY, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in medicaid patients with sickle cell disease and thalassemia. J Med Econ. 2016;19(3):292–303.